CTMX Q4 2021 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CTMXCytomX Therapeutics, Inc.

$846M

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$20M+20.5% YoY

Gross Profit

$18M92.5% margin

Operating Income

-$26M-133.4% margin

Net Income

-$26M-133.0% margin

EPS (Diluted)

$-0.40

QoQ Revenue Growth

+12.2%

Cash Flow

Operating Cash Flow

-$31M

Free Cash Flow

-$31M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$339M

Total Liabilities

$340M

Stockholders' Equity

-$459,000

Cash & Equivalents

$206M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$20M	$16M	+20.5%
Gross Profit	$18M	$16M	+11.4%
Operating Income	-$26M	-$15M	-78.0%
Net Income	-$26M	-$15M	-78.4%